Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis.
CNS
Multiple sclerosis
Neuroinflammation
Prolactin
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 09 2019
15 09 2019
Historique:
received:
12
04
2019
revised:
17
05
2019
accepted:
28
05
2019
pubmed:
8
6
2019
medline:
12
6
2020
entrez:
8
6
2019
Statut:
ppublish
Résumé
Increasing systemic prolactin levels improves remyelination and neuronal survival in animal models of Multiple Sclerosis (MS), but it has been suggested that this therapeutic strategy may also increase inflammatory responses, and potentially harm patients. We analyzed serum prolactin and cytokine, chemokine and growth factor levels in sera from MS patients enrolled in two clinical trials who were treated with domperidone, a generic drug that increases systemic prolactin levels. In patients treated with domperidone, molecule levels changed little during follow up, while prolactin levels increased several-fold. We found no significant association between prolactin levels and radiological or clinical outcome.
Identifiants
pubmed: 31174092
pii: S0165-5728(19)30187-0
doi: 10.1016/j.jneuroim.2019.576974
pii:
doi:
Substances chimiques
Biomarkers
0
Dopamine Antagonists
0
Inflammation Mediators
0
Domperidone
5587267Z69
Prolactin
9002-62-4
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
576974Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.